Darolutamide Shows Promise for Treatment of nmCRPC

The investigational androgen receptor inhibitor darolutamide is poised to shake up the treatment paradigm for men with high-risk nonmetastatic (M0) castration-resistant prostate cancer (nmCRPC), according to results from the ARAMIS trial.

Interim results from the phase 3 trial, presented at the 2019 Genitourinary Cancers Symposium (abstract 140) and simultaneously published in The New England Journal of Medicine (2019;380[13]:1235-1246), showed that darolutamide (Nubeqa, Bayer) doubled median